- Trials with a EudraCT protocol (47)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
47 result(s) found for: Delayed graft function.
Displaying page 1 of 3.
EudraCT Number: 2013-004650-25 | Sponsor Protocol Number: ECU-DGF-201 | Start Date*: 2014-08-12 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multi-Center Study of Eculizumab for the Prevention of Delayed Graft Function after Kidney Transplantation in Adult Subjects at Incre... | |||||||||||||
Medical condition: Delayed Graft Function | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) CZ (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005768-90 | Sponsor Protocol Number: OPN-305-104 | Start Date*: 2013-04-30 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: Follow-up Protocol to the Open-Label Phase 0 Part of the Phase II Opsona Study OPN-305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adap... | |||||||||||||
Medical condition: Prevention of Delayed Graft Function (DGF) following renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002812-33 | Sponsor Protocol Number: 204824 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function ... | |||||||||||||
Medical condition: Delayed Graft Function in Adult Subjects After Renal Transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000131-27 | Sponsor Protocol Number: AC17065 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: Heme arginate in transplantation - a multi-centre blinded parallel-group randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients. (The HOT ... | |||||||||||||
Medical condition: End stage renal disease patients undergoing a deceased donor kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005391-29 | Sponsor Protocol Number: 2021/2014 | Start Date*: Information not available in EudraCT |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effects of mannitol on delayed graft function after cadaveric renal transplantation | ||
Medical condition: Kidney transplantation | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003078-33 | Sponsor Protocol Number: QRK306 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death ... | |||||||||||||
Medical condition: QPI-1002 is being developed for the prevention of Delayed Graft Function in patients receiving renal transplants. The patient population of the current study will include patients undergoing deceas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005767-27 | Sponsor Protocol Number: OPN305-103 | Start Date*: 2014-01-09 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: Follow-up Protocol to the Double-Blind Parts A and B of the Phase II Opsona Study OPN305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Ad... | |||||||||||||
Medical condition: Prevention of Kidney Graft Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) AT (Completed) ES (Ongoing) DE (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003195-12 | Sponsor Protocol Number: CHUBX2012/29 | Start Date*: 2013-10-01 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the fir... | ||
Medical condition: CMV infection in CMV-seropositive de novo kidney transplant recipients receiving an immunosuppressive regimen. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006767-14 | Sponsor Protocol Number: NL79196.018.21 | Start Date*: 2022-08-24 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Alkaline Phosphatase as treatment of Ischemia Reperfusion Injury to prevent delayed graft function | ||
Medical condition: ischemia reperfusion injury in kidneys transplanted from donors after cardiac death | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002594-28 | Sponsor Protocol Number: APHP200036 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Graft Acute kidney injury: vitamin B3 to facilitate renal Recovery In the Early Life of a transplant | |||||||||||||
Medical condition: Patients with end-stage renal failure treated with extrarenal purification (hemodialysis using a catheter or a fistula, or peritoneal dialysis), registered on the national kidney donation waiting l... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005373-22 | Sponsor Protocol Number: 10322 | Start Date*: 2007-07-23 |
Sponsor Name:Central Manchester and Manchester Children's University Hospitals NHS Trust | ||
Full Title: Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors. | ||
Medical condition: Transplantation of renal allografts from extended criteria donors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000210-36 | Sponsor Protocol Number: Euro-NHB | Start Date*: 2007-10-04 |
Sponsor Name:UMC St Radboud University Hospital Center | ||
Full Title: A prospective, randomized, open, multicenter study to evaluate the efficacy and tolerability of induction therapy with a single high-dose anti-T-lymphocyte globulin (ATG-Fresenius) in renal transpl... | ||
Medical condition: Transplantation of a renal graft from a non-heart-beating donor | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004311-23 | Sponsor Protocol Number: HOTstudy_Thomas11 | Start Date*: 2011-11-29 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants. | ||||||||||||||||||
Medical condition: Ischaemia-reperfusion injury in renal transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2010-020989-20 | Sponsor Protocol Number: QRK.006 Part B | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patie... | |||||||||||||
Medical condition: I5NP is being developed for the prophylaxis of delayed graft function (DGF) in patients receiving renal transplants. The patient population of the current study will include patients undergoing dec... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000340-34 | Sponsor Protocol Number: OPTIMUS | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE | |||||||||||||
Full Title: Dose optimization of tacrolimus using Bayesian prediction including pharmacogenetic variables in renal transplant patients. | |||||||||||||
Medical condition: PROPHYLAXIS OF ALLOGRAFT REJECTION AFTER RENAL TRASPLANT. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002640-70 | Sponsor Protocol Number: 20-HMedIdeS-19 | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Hansa Biopharma AB | |||||||||||||
Full Title: A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase tre... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005238-21 | Sponsor Protocol Number: CRAD001ADE44 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: 12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in c... | |||||||||||||
Medical condition: Kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002866-19 | Sponsor Protocol Number: CRAD001AIT25 | Start Date*: 2011-07-25 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A 3-month, multicenter, randomized, open label study to evaluate the impact of early vs delayed introductioN of EVERolimus on WOUND healing in de novo kidney transplant recipients (NEVERWOUND study) | |||||||||||||
Medical condition: Renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000830-11 | Sponsor Protocol Number: RL05/7239 | Start Date*: 2006-07-26 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy | ||
Medical condition: MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001587-30 | Sponsor Protocol Number: 012657 | Start Date*: 2019-07-26 | ||||||||||||||||
Sponsor Name:Queen Mary University London | ||||||||||||||||||
Full Title: AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce | ||||||||||||||||||
Medical condition: renal transplant AND type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
